Related Blog Posts from the Wikinvest Wire

Amgen (AMGN)   Subscribe to Amgen (AMGN) content from the Wikinvest Wire
 » Back to Amgen (NASDAQ:AMGN) Stock Page

  

6/19/15Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Presents Open-Label Extension Data From Ongoing P... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., June 19, 2015 /PRNewswire/ -- Amgen (AMGN) today announced positive interim results from its open-label extension of the global Phase 2, double-blind, placebo-controlled study evaluating the safety and efficacy of AMG 334 for the prevention of episodic migraine. Patients who entered the open-label phase received AMG 334 70 [...]

6/10/15Stock Update: Amgen Inc (NASDAQ:AMGN) – FDA panel backs Amgen’s cholesterol drug for high-ris... (Jutia Group)

[Reuters] - An advisory panel to the U.S. Food and Drug Administration recommended approval of Amgen Inc's cholesterol-lowering drug Repatha but said it should be only used in patients at high risk of cardiovascular disease. The panel voted unanimously to approve the drug, known also as evolocumab, for patients with homozygous familial hypercholesterolemia (HoFH), [...]

6/10/15Stock Update: Merck & Co Inc (NYSE:MRK) – Merck and Samsung Bioepis Announce Pivotal Phase 3 St... (Jutia Group)

[Business Wire] - Merck , known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd. today announced that pivotal Phase 3 clinical studies of SB4, an investigational biosimilar of Enbrel , and SB2, an investigational biosimilar of Remicade , met their primary endpoints, demonstrating equivalence to the originator medicine in [...]

6/10/15Recent Buy – Amgen Inc (The DIV-Net)

A cornerstone of dividend growth investing is to stay focused on buying quality assets and ignoring the noise surrounding uncontrollable parts of the economy. I have employed this measure and look for decent opportunities whether the stock market is up or down. My only focus is to increase my dividends year after year and try not to time the market in order to attempt outperformance. While there are some good value finds in sectors such as energy, commodities and financials, one sector...

6/8/15Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen’s Repatha effective; question is for which pat... (Jutia Group)

[Reuters] - Amgen Inc's experimental drug Repatha lowered cholesterol in clinical trials and did not cause a marked disparity in deaths or serious adverse events but showed potential safety issues that should be explored, according to a preliminary review by the U.S. Food and Drug Administration. The review was published on Monday on the [...]

6/1/15Market Update (NASDAQ:AMGN): Amgen Presents Phase 3 Data At ASCO Showing Prolia® (Denosumab) Sig... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., June 1, 2015 /PRNewswire/ -- Amgen (AMGN) today announced results from a randomized, double-blind, placebo-controlled, multicenter Phase 3 study evaluating the treatment effect of adjuvant Prolia® (denosumab), 60 mg once every six months, therapy in postmenopausal women with early hormone receptor positive (HR+) breast cancer receiving aromatase inhibitor [...]

5/27/15Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen To Advance Understanding Of The Treatment Of Bl... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., May 27, 2015 /PRNewswire/ -- Amgen (AMGN) today announced that it will present data from multiple Kyprolis® (carfilzomib) for Injection, BLINCYTO® (blinatumomab), oprozomib and Nplate® (romiplostim)‎ studies at the 20th Congress of the European Hematology Association (EHA) taking place in Vienna, June 11 - 14, 2015. The data [...]

5/22/15Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Receives Positive CHMP Opinion For Use Of Repatha... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., May 22, 2015 /PRNewswire/ -- Amgen (AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of Repatha™ (evolocumab) recommending approval for use in certain patients with high cholesterol. Read [...]

5/19/15Market Update (NASDAQ:AMGN): Amgen cholesterol drug could get EU green light this week (Jutia Group)

[Reuters] - Amgen's new cholesterol drug Repatha could be recommended for approval in Europe as early as this week, putting it ahead in a race with a rival product from Sanofi. Repatha, or evolocumab, belongs to a new class of cholesterol-lowering drugs known as PCSK9 inhibitors that clinical trials suggest may slash the risks [...]

5/18/15Company Update (NASDAQ:AMGN): Amgen Appoints Jonathan P. Graham Senior Vice President, General Co... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., May 18, 2015 /PRNewswire/ -- Amgen (AMGN) today announced the appointment of Jonathan P. Graham as senior vice president, general counsel and secretary, effective July 13, 2015. He will be responsible for Amgen's legal operations, reporting to Robert A. Bradway, chairman and chief executive officer. Graham will succeed [...]

5/14/15Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Voting Results of Annual Meeting of St... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., May 14, 2015 /PRNewswire/ -- Amgen (AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village, Calif. Approximately 89 percent of outstanding shares were represented at the meeting. The director nominees David Baltimore, Frank J. Biondi, Jr., Robert A. Bradway, François de [...]

5/12/15Company Update (NASDAQ:AMGN): Amgen’s Breakaway From Cancer® Announces Winners Of Its Nationwi... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., May 12, 2015 /PRNewswire/ -- Amgen (AMGN) today announced the 10 Breakaway from Cancer® Champions selected from a nationwide search for survivors, patients, caregivers and advocates who have inspired those affected by cancer. These extraordinary individuals will join breast cancer survivor and Honorary Breakaway from Cancer Champion Joan [...]

5/11/15Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen To Present AMG 334 Data At 17th Congress of the ... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., May 11, 2015 /PRNewswire/ -- Amgen (AMGN) today announced it will be presenting data for its calcitonin gene-related peptide (CGRP) receptor inhibitor AMG 334 at the 17th Congress of the International Headache Society (IHC 2015) in Valencia, Spain. AMG 334 is a fully human monoclonal antibody under investigation [...]

5/4/15Stock Update (NASDAQ:AMGN): Amgen To Present At The Deutsche Bank 40th Annual Healthcare Conference (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., May 4, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Deutsche Bank 40th Annual Healthcare Conference at 8 a.m. ET on Thursday, May 7, 2015, at the InterContinental ... Read more on this. Amgen Inc. (AMGN), valued at $123.20B, opened at $161.50.   [...]

4/29/15Market Update: Amgen Inc (NASDAQ:AMGN) – FDA panel recommends approval for Amgen’s skin cance... (Jutia Group)

[Reuters] - Amgen Inc's skin cancer immunotherapy showed enough efficacy in the treatment of melanoma to be given marketing approval, an independent advisory panel to the U.S. Food and Drug Administration said on Wednesday. The panel voted 22-1 supporting an approval for the therapy, talimogene laherparepvec or "T-Vec", an engineered virus that kills cancer [...]

4/27/15Market Update (NASDAQ:AMGN): Amgen’s cancer immunotherapy fails to impress FDA staff reviewers (Jutia Group)

[Reuters] - U.S. Food and Drug Administration staff reviewers said an accelerated review of drugmaker Amgen Inc's skin cancer immunotherapy cannot be considered at this time, citing concerns over the design and results of a key study. The review comes two days before a panel of FDA advisers votes on whether T-Vec should be [...]

4/22/15Company Update (NASDAQ:AMGN): Amgen tops estimates, grows profit 51% (Jutia Group)

[AAP] - Amgen Inc has boosted its first-quarter profit by 51 per cent, thanks to surging drug sales and ongoing cost cuts designed to free up cash for an unprecedented burst of new product launches. Repatha is part of a new class of pricey cholesterol drugs called PCSK9 inhibitors aimed at patients not helped [...]

4/16/15Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Webcast Of 2015 First Quarter Financia... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., April 16, 2015 /PRNewswire/ -- Amgen (AMGN) today announced that it will report its first quarter financial results on Tuesday, April 21, 2015, after the close of the U.S. financial markets. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and [...]

4/15/15Stock Update (NASDAQ:AMGN): U.S. FDA approves Amgen heart failure drug (Jutia Group)

[Reuters] - U.S. health regulators on Wednesday approved Amgen Inc's Corlanor to treat patients with chronic heart failure, giving the world's largest biotechnology company its first cardiovascular medicine product. ... Read more on this. Amgen Inc. (AMGN), with a current market cap of $125.57B, started the session at $163.12.   [...]

3/30/15Stock Update (NASDAQ:AMGN): Amgen To Present At The Goldman Sachs Key Debates In Biosimilars Conf... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., March 30, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Goldman Sachs Key Debates in Biosimilars conference at 9:05 a.m. ET on Thursday, April 2, 2015, at the Goldman ... Read more on this. Amgen Inc. (AMGN), currently valued at $124.68B, opened at $164.51. [...]

3/25/15Company Update (NASDAQ:AMGN): Amgen to appeal rejection of bid to block Novartis biosimilar drug (Jutia Group)

[Reuters] - Amgen Inc will appeal the rejection of its bid to block the sale of Novartis AG's biosimilar form of Neupogen, Amgen's blockbuster drug used to prevent infections in cancer patients, according to a court filing on Wednesday. The drug, Zarxio, contains the same active ingredient as Amgen's $1.2 billion-a-year Neupogen, and once [...]

3/2/15Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Launch Of New Neulasta® (Pegfilgrasti... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., March 2, 2015 /PRNewswire/ -- Amgen (AMGN) today announced that the Neulasta® (pegfilgrastim) Delivery Kit is now available in the United States (U.S.). The Neulasta Delivery Kit includes a specially designed single-use prefilled syringe co-packaged with the new On-body Injector for Neulasta. Read more on this. Amgen [...]

2/26/15 (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Feb. 26, 2015 /PRNewswire/ -- Amgen (AMGN) and its subsidiary Onyx Pharmaceuticals, Inc., today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) of Kyprolis® (carfilzomib) for Injection for the treatment of patients with relapsed multiple myeloma who [...]

2/11/15Company Update (NASDAQ:AMGN): Amgen Announces FDA Advisory Committees To Review Talimogene Laherp... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Feb. 11, 2015 /PRNewswire/ -- Amgen (AMGN) announced today that the Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) and the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) will jointly review the Company's Biologics License Application (BLA) for talimogene laherparepvec. The FDA [...]

1/27/15Market Update (NASDAQ:AMGN): Amgen Submits Applications In The US And Europe For Kyprolis® (carf... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Jan. 27, 2015 /PRNewswire/ -- Amgen (AMGN) and its subsidiary Onyx Pharmaceuticals, Inc., today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency [...]

1/15/15Market Update (NASDAQ:AMGN): Amgen Presents New Data Supporting First-Line Use Of Vectibix® (Pan... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Jan. 15, 2015 /PRNewswire/ -- Amgen (AMGN) today announced new data from the Phase 2 PEAK and Phase 3 PRIME studies that support the first-line use of Vectibix® (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, in patients with wild-type RAS (absence of exons 2, 3, or [...]

1/12/15Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen and MD Anderson Announce Agreement to Develop B... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif. and HOUSTON, Jan. 12, 2015 /PRNewswire/ -- Amgen (AMGN) and The University of Texas MD Anderson Cancer Center today announced a research collaborative agreement focusing on Amgen's bispecific T cell engager (BiTE®) antibody constructs, an immunotherapy that serves as a "bridge" between T cells and cancer cells. "This [...]

1/8/15Company Update (NASDAQ:AMGN): Amgen To Present At The 33rd Annual J.P. Morgan Healthcare Conference (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Jan. 8, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the 33 rd Annual J.P. Morgan Healthcare Conference at 9:30 a.m. PT on Tuesday, Jan. 13, 2015, at the Westin St. ... Read more on this. Amgen Inc. (AMGN), valued at $119.93B, opened this morning at [...]

1/5/15Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen, Kite Pharma ink deal to develop cancer immunot... (Jutia Group)

[Reuters] - Amgen Inc and Kite Pharma Inc said they entered into a deal to develop and market cancer immunotherapies using Amgen's cancer targets and Kite's technology platform. Amgen will pay Kite Pharma $60 million ... Read more on this. Amgen Inc. (AMGN), with a current market cap of $120.57B, started trading this [...]

12/17/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces 30 Percent Increase In 2015 First Quart... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Dec. 17, 2014 /PRNewswire/ -- Amgen (AMGN) today announced that its Board of Directors declared a $0.79 per share dividend for the first quarter of 2015. Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative [...]

12/11/14Company Update (NASDAQ:AMGN): Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1™ ... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif. and LONDON, Dec. 11, 2014 /PRNewswire/ -- Amgen (AMGN) and AstraZeneca (AZN) today announced that additional results from AMAGINE-1TM, a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab in patients with moderate-to-severe plaque psoriasis will be presented at the Psoriasis: From Gene to Clinic International Congress [...]

12/3/14Company Update: Amgen Inc (NASDAQ:AMGN) – Actress Adamari López And Amgen Launch Spanish-Langu... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Dec. 3, 2014 /PRNewswire/ -- Amgen (AMGN) today launched Quimioterapia: Mitos y Realidades, a Spanish-language extension of the Chemotherapy: Myths or FactsTM awareness initiative for cancer patients and their caregivers, featuring actress and Emmy® award-winning television personality Adamari López. In 2005, López was diagnosed with and treated for [...]

11/24/14Stock Update (NASDAQ:AMGN): Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies O... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Nov. 24, 2014 /PRNewswire/ -- Amgen (AMGN) today announced the termination of all Amgen-sponsored clinical studies of rilotumumab in advanced gastric cancer, including the Phase 3 RILOMET-1 and RILOMET-2 studies. Amgen's decision is based on a planned safety review by the RILOMET-1 independent data monitoring committee that found [...]

11/18/14Company Update (NASDAQ:AMGN): Amgen Presents Long-Term Data Showing Efficacy And Safety Of Invest... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Nov. 18, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from three separate analyses of Phase 2 and 3 studies evaluating evolocumab, a novel investigational low-density ... Read more on this. Amgen Inc. (AMGN), valued at $123.41B, opened at $158.83.   Today’s price [...]

11/14/14Company Update (NASDAQ:AMGN): Amgen To Present At The Jefferies Global Healthcare Conference (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Nov. 14, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will participate at the Jefferies Global Healthcare Conference on Wednesday, Nov. 19, 2014, in London, beginning at 8:40 a.m. GMT. ... Read more on this. Amgen Inc. (AMGN), with a current market cap of $119.94B, started trading this morning [...]

11/12/14Stock Update (NASDAQ:AMGN): The Amgen Foundation Expands Amgen Scholars Program to 17 Top Educati... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Nov. 12, 2014 /PRNewswire/ -- The Amgen Foundation today announced that the Amgen Scholars Program is expanding its presence with new host institutions in the U.S., Europe, and, ... Read more on this. Amgen Inc. (AMGN), with a current value of $123.02B, finished at $162.42.   [...]

11/10/14Stock Update: Amgen Inc (NASDAQ:AMGN) – FDA Accepts Amgen’s Biologics License Application For... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Nov. 10, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen's Biologics License Application ... Read more on this. Amgen Inc. (AMGN), valued at $123.63B, opened at $161.01.   Looking at the [...]

11/6/14Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen Highlights New Data In The Treatment Of Blood C... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Nov. 6, 2014 /PRNewswire/ -- Amgen (AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that more than 50 abstracts from the Company's oncology and hematology portfolios have been accepted for presentation at the 56th Annual Meeting and Exposition of the American Society [...]

11/4/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen ovarian cancer drug fails to improve overall surv... (Jutia Group)

[Reuters] - Amgen Inc said its experimental ovarian cancer drug did not show statistically significant improvement in overall survival rate in a late-stage trial. Statistically significant improvement in overall survival was the secondary goal of the trial. The trial, TRINOVA-1, is the first of three late-stage studies to evaluate safety and effectiveness of the [...]

10/29/14iShares NASDAQ Biotechnology Index Tops: Amgen, Gilead Exhaustion (The Market Financial)

Just a couple months ago, Janet Yellen issued a warning that biotechnology may be in a bubble. Today, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) are 20% higher. While Janet Yellen was wrong at the time, we should all remember that Alan Greenspan issued the same warning on Dot.com companies in the late 1990's. He [...]

10/28/14Market Update (NASDAQ:AMGN): Amgen Outlines Strategy, Growth Objectives And Capital Allocation Plans (Jutia Group)

[PR Newswire] - NEW YORK, Oct. 28, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today outlined the Company's strategy, growth objectives and capital allocation plans, and provided financial guidance for 2015. Robert A. Bradway, ... Read more on this. Amgen Inc. (AMGN), valued at $118.95B, began trading this morning at $151.75.   [...]

10/23/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen To Webcast 2014 Business Review Meeting On Octobe... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Oct. 23, 2014 /PRNewswire/ -- Amgen (AMGN) today announced that it will hold its Business Review Meeting on Tuesday, Oct. 28, 2014, at the Conrad New York, 102 North End Avenue, New York City, beginning at 8 a.m. ET. In the meeting, Robert A. Bradway, chairman and chief [...]

10/21/14Company Update (NASDAQ:AMGN): Amgen Statement Regarding Third Point Investment (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Oct. 21, 2014 /PRNewswire/ -- Amgen (AMGN) issued the following statement with respect to media inquiries concerning Third Point LLC's equity position in Amgen: Amgen maintains an active, engaged dialogue with all shareholders. Amgen has always appreciated the perspectives of all of its shareholders, including Third Point, and [...]

10/17/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Appointment Of R. Sanders Williams To B... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Oct. 17, 2014 /PRNewswire/ -- Amgen (AMGN) today announced the appointment of R. Sanders Williams, M.D., president of Gladstone Institutes and Gladstone's Robert W. and Linda L. Mahley Distinguished Professor. "We are pleased to welcome Dr. Sandy Williams to the Amgen Board," said Robert A. Bradway, chairman and [...]

9/22/14Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen Submits Biologics License Application for Inves... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Sept. 22, 2014 /PRNewswire/ -- Amgen (AMGN) today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval for its investigational bispecific T cell engager (BiTE®) antibody construct, blinatumomab. The BLA is for the treatment of adults with Philadelphia-negative (Ph-) [...]

9/15/14Company Update (NASDAQ:AMGN): Amgen Announces Results From Several New Exploratory Analyses Evalu... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Sept. 15, 2014 /PRNewswire/ -- Amgen (AMGN) today announced results from a new exploratory analysis of the open-label extension study of the pivotal Phase 3 fracture trial, which found that treatment with Prolia® (denosumab) for eight years enabled a substantial proportion of women with osteoporosis to achieve non-osteoporotic [...]

9/10/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces 23 Abstracts To Be Presented At The Ame... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Sept. 10, 2014 /PRNewswire/ -- Amgen (AMGN) today announced that it will present data from multiple Prolia® (denosumab) and romosozumab study analyses at the American Society for Bone and Mineral Research (ASBMR) 2014 Annual Meeting being held in Houston, Sept. 12-15, 2014. The data that will be presented [...]

9/2/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Submits Marketing Authorization Application For T... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Sept. 2, 2014 /PRNewswire/ -- Amgen (AMGN) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized procedure for talimogene laherparepvec seeking approval for the treatment of adults with melanoma that is regionally or distantly metastatic. Talimogene laherparepvec is [...]

8/28/14Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen submits U.S. application to sell cholesterol-fi... (Jutia Group)

[Reuters] - Amgen Inc said it submitted an application to the U.S. Food and Drug Administration to market its cholesterol-lowering drug, evolocumab. The injectable drug works by blocking PCSK9, a naturally occurring ... Read more on this. Amgen Inc. (AMGN), valued at $105.54B, started the session at $137.65.   Looking [...]

8/27/14Stock Update: Amgen Inc (NASDAQ:AMGN) – FDA Grants Amgen Priority Review Designation For Ivabra... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Aug. 27, 2014 /PRNewswire/ -- Amgen (AMGN) today announced the U.S. Food and Drug Administration (FDA) has granted priority review designation for ivabradine for the treatment of chronic heart failure (HF). Ivabradine is an oral drug that inhibits the If current ("funny" current) in the sinoatrial node, the [...]


Your blog posts can appear here by joining the Wikinvest Wire
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki